FRANKLIN M BERGER
CIK 1273885 · Director · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.77M
Companies
13
Total Filings
118
Lifetime Open-Market Net
$11.27M
Filer Profile
Reported Address
C/O ATEA PHARMACEUTICALS, INC.225 FRANKLIN STREET SUITE 2100
BOSTON, MA
Related Filers
Lineage Cell Therapeutics, Inc. — 3 joint filings, latest 2013-08-22
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVIR | Director | 536,097 | $5.17 | $2.77M | -$238.2K | 13 | 2026-06-23 |
| Kezar Life Sciences, Inc. (KZR) Delisted | Director | 0 | $7.29 | $0 | $2.91M | 14 | 2026-05-11 |
| ESSA Pharma Inc. (EPIX) Delisted | Director | 784,404 | $0.20 | $157.8K | $1.36M | 8 | 2024-03-28 |
| RAIN | Director | 0 | $1.00 | $0 | $3.41M | 8 | 2024-01-26 |
| Atreca, Inc. (BCEL) Delisted | Director | 97,808 | $0.15 | $14.7K | $0 | 5 | 2023-06-15 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Director | 0 | $38.00 | $0 | $1.20M | 13 | 2021-04-19 |
| KINETA, INC./DE (PTI) Delisted | Director | 15,308 | — | — | $2.12M | 10 | 2020-07-01 |
| Forte Biosciences, Inc. (TOCA) Delisted | Director | 1,689 | — | — | $0 | 4 | 2019-10-04 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | — | $178.75 | — | $0 | 4 | 2019-06-12 |
| Seagen Inc. (SGEN) Delisted | Director | 204,720 | $228.74 | $46.83M | $505.2K | 20 | 2014-02-25 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 500 | — | — | $1.9K | 2 | 2013-08-22 |
| EMIS | Director | — | $10.27 | — | $0 | 1 | 2009-05-19 |
| Diadexus, Inc. (AXC) Delisted | Director | — | — | — | $0 | 1 | 2008-06-11 |
Recent Filings · Page 12 of 12
118 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-07-30 | Seagen Inc. (SGEN) Delisted | Exer (M) | +5,000 | $20.9K | EDGAR |
| 2009-05-19 | EMIS | Grant (A) | — | $0 | EDGAR |
| 2009-05-19 | Seagen Inc. (SGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-06-11 | Diadexus, Inc. (AXC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-05-20 | Seagen Inc. (SGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-01-24 | Seagen Inc. (SGEN) Delisted | Buy (P) | +528 | $4.8K | EDGAR |
| 2007-05-30 | Seagen Inc. (SGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-02-15 | — | Grant (A) | — | $0 |
Showing 111–118 of 118
Prev
Page 12 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.